Clinical Trial: Azithromycin to Modify Bronchiectasis Exacerbation Risk

U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07608328) titled 'Azithromycin to Modify Bronchiectasis Exacerbation Risk' on May 15.

Brief Summary: The Azithromycin to Modify Bronchiectasis Exacerbation Risk (AMBER) trial is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial in adults with clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).

The trial evaluates whether azithromycin 250 mg orally once daily for 12 months, added to standard bronchiectasis care, reduces the occurrence of at least one bronchiectasis exacerbation during 12-month follow-up compared with matching placebo added to standard bronchiectasis care.

Partici...